TipRanks
Xvivo Perfusion AB (DE:3XV)
FRANKFURT:3XV

Xvivo Perfusion AB (3XV) Price & Analysis

0 Followers

3XV Stock Chart & Stats

€25.14
-€0.50(-2.30%)
At close: 4:00 PM EDT
€25.14
-€0.50(-2.30%)

Bulls Say, Bears Say

Bulls Say
Strong Organic Revenue GrowthStrong organic growth demonstrates increasing demand for XVIVO’s transplantation solutions and supports expansion of its commercial platform. As adoption increases, procedure-linked consumables and services can create a broader recurring revenue base, strengthening the company’s medium-term growth profile.
Thoracic Momentum And Margin StrengthThoracic growth combines rapid demand expansion with a high gross-margin profile, making it an important source of scalable earnings. Strong disposable growth also indicates increasing utilization of the installed clinical platform, which can support durable revenue and profit progression.
Very Conservative Balance SheetVery low leverage reduces refinancing risk and gives XVIVO capacity to fund regulatory work, commercial expansion and production scale-up without relying heavily on external financing. This financial flexibility is a durable advantage while the company pursues multi-year adoption opportunities.
Bears Say
Abdominal Margin PressureLower abdominal margins weaken consolidated profitability and show that revenue growth does not automatically translate into proportionate earnings growth. Reliance on lower-margin kidney mix and pricing pressure may continue to constrain margin expansion until geography, costs and process efficiency improve.
Services Segment WeaknessServices weakness reduces both revenue diversification and current contribution margins, while underutilized capacity indicates operating inefficiency. Persistent softness in organ recovery volumes could limit earnings scalability and require further commercial or capacity adjustments before the segment improves.
Regulatory Timing RiskUncertain regulatory timing can delay launches, market access and the conversion of clinical progress into commercial revenue. Delays would also prolong investment requirements and defer the volume benefits expected from heart expansion, increasing execution risk over the next several quarters.

Xvivo Perfusion AB News

3XV FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was €14.45 and its highest was €28.42 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is €705.03M.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Oct 22, 2026 which is in 36 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Jul 14, 2026. The company reported €0.059 earnings per share for the quarter, missing the consensus estimate of €0.068 by -€0.009.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.07.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of €0.059 in its last earnings report, missing expectations of €0.068. Following the earnings report the stock price went down -3.349%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in DE:3XV
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (3XV) Earnings & Revenues

                    3XV Company Deck

                    3XV Earnings Call

                    Q2 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presents a predominantly positive operational and financial picture: strong organic revenue growth (36% in Q2), robust profitability (19% Q2 EBITDA margin; rolling 12-month EBITDA 21%) and improving cash generation (positive operating cash flow and SEK 305m cash balance). Commercial momentum is broad-based (notably thoracic/EVLP, kidney, and heart pre-launch adoption) and supported by strong clinical evidence (heart trial outcomes and >600 heart transplants). Key risks include services underperformance, margin pressure in abdominal products driven by mix and pricing, elevated R&D/CapEx and regulatory timing uncertainty (CE mark and U.S. pathways). Overall the positive growth, profitability and clinical/regulatory progress outweigh the identifiable execution and timing risks.View all DE:3XV earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    Vitrolife AB
                    BICO Group AB Class B
                    SciBase Holding AB
                    Sedana Medical AB
                    Popular Stocks